50 results on '"Gold, Kathryn A."'
Search Results
2. Spatial PD‐L1, immune‐cell microenvironment, and genomic copy‐number alteration patterns and drivers of invasive‐disease transition in prospective oral precancer cohort
- Author
-
William, William N, Zhang, Jianjun, Zhao, Xin, Parra, Edwin R, Uraoka, Naohiro, Lin, Heather Y, Peng, S Andrew, El‐Naggar, Adel K, Rodriguez‐Canales, Jaime, Song, Jaejoon, Gillenwater, Ann M, Wistuba, Ignacio I, Myers, Jeffrey N, Gold, Kathryn A, Ferrarotto, Renata, Hwu, Patrick, Davoli, Teresa, Lee, J Jack, Heymach, John V, Papadimitrakopoulou, Vassiliki A, and Lippman, Scott M
- Subjects
Biomedical and Clinical Sciences ,Oncology and Carcinogenesis ,Immunology ,Dental/Oral and Craniofacial Disease ,Cancer ,Rare Diseases ,Clinical Research ,Humans ,B7-H1 Antigen ,Biomarkers ,Tumor ,Genomics ,Head and Neck Neoplasms ,Lymphocytes ,Tumor-Infiltrating ,Mouth Neoplasms ,Neoplasm Recurrence ,Local ,Prospective Studies ,Squamous Cell Carcinoma of Head and Neck ,Tumor Microenvironment ,copy-number alterations ,genomics ,head and neck cancer ,HPV ,immune profiling ,PD-L1 ,precancer ,T-cells ,tumor microenvironment ,Public Health and Health Services ,Oncology & Carcinogenesis ,Oncology and carcinogenesis ,Public health - Abstract
BackgroundStudies of the immune landscape led to breakthrough trials of programmed death-1 (PD-1) inhibitors for recurrent/metastatic head and neck squamous cell carcinoma therapy. This study investigated the timing, influence of somatic copy-number alterations (SCNAs), and clinical implications of PD-L1 and immune-cell patterns in oral precancer (OPC).MethodsThe authors evaluated spatial CD3, CD3/8, and CD68 density (cells/mm2 ) and PD-L1 (membranous expression in cytokeratin-positive intraepithelial neoplastic cells and CD68) patterns by multiplex immunofluorescence in a 188-patient prospective OPC cohort, characterized by clinical, histologic, and SCNA risk factors and protocol-specified primary end point of invasive cancer. The authors used Wilcoxon rank-sum and Fisher exact tests, linear mixed effect models, mediation, and Cox regression and recursive-partitioning analyses.ResultsEpithelial, but not CD68 immune-cell, PD-L1 expression was detected in 28% of OPCs, correlated with immune-cell infiltration, 9p21.3 loss of heterozygosity (LOH), and inferior oral cancer-free survival (OCFS), notably in OPCs with low CD3/8 cell density, dysplasia, and/or 9p21.3 LOH. High CD3/8 cell density in dysplastic lesions predicted better OCFS and eliminated the excess risk associated with prior oral cancer and dysplasia. PD-L1 and CD3/8 patterns revealed inferior OCFS in PD-L1 high intrinsic induction and dysplastic immune-cold subgroups.ConclusionThis report provides spatial insight into the immune landscape and drivers of OPCs, and a publicly available immunogenomic data set for future precancer interrogation. The data suggest that 9p21.3 LOH triggers an immune-hot inflammatory phenotype; whereas increased 9p deletion size encompassing CD274 at 9p24.1 may contribute to CD3/8 and PD-L1 depletion during invasive transition. The inferior OCFS in PD-L1-high, immune-cold OPCs support the development of T-cell recruitment strategies.
- Published
- 2023
3. Clinicopathologic and molecular characteristics of EGFR-mutant lung adenocarcinomas that transform to small cell lung cancer after TKI therapy.
- Author
-
Yu, Li, Bazhenova, Lyudmila, Gold, Kathryn, Tran, Lisa, Hilburn, Van, Vu, Peter, and Patel, Sandip Pravin
- Subjects
EGFR mutation ,Lung adenocarcinoma ,small cell lung cancer ,transformation ,tyrosine kinase inhibitor ,Rare Diseases ,Lung ,Genetics ,Cancer ,Lung Cancer ,6.1 Pharmaceuticals ,Evaluation of treatments and therapeutic interventions ,tyrosine ,kinase inhibitor ,Clinical Sciences ,Oncology and Carcinogenesis - Abstract
BackgroundSmall cell lung cancer (SCLC) transformation is one of the mechanisms of drug resistance to tyrosine kinase inhibitors (TKIs) in advanced epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer (NSCLC) and represents an increasingly recognized clinical dilemma.MethodsWe performed a retrospective review of 964 cases at the University of California, San Diego of patients with EGFR sensitizing mutations. Nine patients had a biopsy-confirmed small cell transformation. The unique gene alterations and clinicopathologic features were collected and analyzed.ResultsNine cases (9/964, 0.9%) were identified, all with stage IV adenocarcinoma (ADC) at diagnosis, 7 were poorly differentiated, and 7 had an EGFR exon 19 deletion. All nine patients had tumor protein p53 (TP53) mutation. Among seven cases that had next-generation sequencing (NGS), 5 harbored retinoblastoma 1 (RB1) loss. WNK lysine deficient protein kinase 1 (WNK1) mutation was found in two patients that had longer survival. The median time from the initial diagnosis to transformation was 22.7 months (IQR: 15.1-25.1). After small cell transformation on EGFR inhibition, all patients were treated with etoposide/platinum, conferring a median progression-free survival (PFS) of 3.2 months (IQR, 2.2-6.5 months) and post-chemotherapy survival of 8.6 months (IQR, 4.0-19.0 months). Six patients, as they retained the initial EGFR mutations, resumed (did so after terminating chemotherapy)/continued (did so concomitantly with chemotherapy) TKIs with a median duration of 13.8 months (IQR, 3.8-27.7 months). Two patients received immunotherapy but had no benefit.ConclusionsIn our series, most patients with small cell transformation had poorly differentiated adenocarcinomas at baseline. RB1 loss was not universal in transformed patients in this series, though TP53 mutation was present in all tumor samples. WNK1 mutation may be a new resistance mechanism to TKIs that may be associated with improved survival.
- Published
- 2022
4. Efficacy and Safety of Patritumab Deruxtecan (HER3-DXd) in EGFR Inhibitor–Resistant, EGFR-Mutated Non–Small Cell Lung CancerHER3-DXd in EGFR TKI–Resistant EGFR-Mutated NSCLC
- Author
-
Jänne, Pasi A, Baik, Christina, Su, Wu-Chou, Johnson, Melissa L, Hayashi, Hidetoshi, Nishio, Makoto, Kim, Dong-Wan, Koczywas, Marianna, Gold, Kathryn A, Steuer, Conor E, Murakami, Haruyasu, Yang, James Chih-Hsin, Kim, Sang-We, Vigliotti, Michele, Shi, Rong, Qi, Zhenhao, Qiu, Yang, Zhao, Lihui, Sternberg, David, Yu, Channing, and Yu, Helena A
- Subjects
Biomedical and Clinical Sciences ,Clinical Sciences ,Oncology and Carcinogenesis ,Cancer ,Lung ,Lung Cancer ,Clinical Research ,Development of treatments and therapeutic interventions ,6.1 Pharmaceuticals ,Evaluation of treatments and therapeutic interventions ,5.1 Pharmaceuticals ,Aged ,Antibodies ,Monoclonal ,Humanized ,Antineoplastic Agents ,Immunological ,Camptothecin ,Carcinoma ,Non-Small-Cell Lung ,Disease-Free Survival ,Dose-Response Relationship ,Drug ,ErbB Receptors ,Female ,Humans ,Infusions ,Intravenous ,Lung Neoplasms ,Male ,Middle Aged ,Neoplasm Metastasis ,Treatment Outcome ,Biochemistry and cell biology ,Oncology and carcinogenesis - Abstract
Receptor tyrosine-protein kinase ERBB3 (HER3) is expressed in most EGFR-mutated lung cancers but is not a known mechanism of resistance to EGFR inhibitors. HER3-DXd is an antibody-drug conjugate consisting of a HER3 antibody attached to a topoisomerase I inhibitor payload via a tetrapeptide-based cleavable linker. This phase I, dose escalation/expansion study included patients with locally advanced or metastatic EGFR-mutated non-small cell lung cancer (NSCLC) with prior EGFR tyrosine kinase inhibitor (TKI) therapy. Among 57 patients receiving HER3-DXd 5.6 mg/kg intravenously once every 3 weeks, the confirmed objective response rate by blinded independent central review (Response Evaluation Criteria in Solid Tumors v1.1) was 39% [95% confidence interval (CI), 26.0-52.4], and median progression-free survival was 8.2 (95% CI, 4.4-8.3) months. Responses were observed in patients with known and unknown EGFR TKI resistance mechanisms. Clinical activity was observed across a broad range of HER3 membrane expression. The most common grade ≥3 treatment-emergent adverse events were hematologic toxicities. HER3-DXd has clinical activity in EGFR TKI-resistant cancers independent of resistance mechanisms, providing an approach to treat a broad range of drug-resistant cancers. SIGNIFICANCE: In metastatic EGFR-mutated NSCLC, after disease progression on EGFR TKI therapy, treatment approaches include genotype-directed therapy targeting a known resistance mechanism or chemotherapy. HER3-DXd demonstrated clinical activity spanning known and unknown EGFR TKI resistance mechanisms. HER3-DXd could present a future treatment option agnostic to the EGFR TKI resistance mechanism.See related commentary by Lim et al., p. 16.This article is highlighted in the In This Issue feature, p. 1.
- Published
- 2022
5. A framework and road map for rapid start-up and completion of a COVID-19 vaccine trial: A single clinical trial site experience
- Author
-
Rojas, Carlos, Spector, Stephen A, Cale, Bernadette, Loughran, Megan, Lazaro, Leander, Mah, Eric, Firestein, Gary S, Gold, Kathryn A, and Wallace, Mark
- Subjects
Engineering ,Commerce ,Management ,Tourism and Services ,Strategy ,Management and Organisational Behaviour ,Clinical Research ,Prevention ,Immunization ,Vaccine Related ,Clinical Trials and Supportive Activities ,Good Health and Well Being ,COVID-19 vaccine ,study start up ,clinical trial project management ,rapid enrollment ,scalable systems - Abstract
The COVID-19 global pandemic required the rapid development of vaccines with a quick start up of phase 1-3 studies with large enrollment targets. The University of California San Diego was identified as a site for the phase 3 trial of the mRNA-1273-SARS-CoV-2 vaccine. There were many challenges with scaling up a large-scale clinical trial in such a short time. This report describes the processes and procedures that were implemented to successfully complete the enrollment target in under 10 weeks. This required the team to identify existing tools that could rapidly be accessed to develop a database, scheduling system, effective communication, document management, staff time tracking/efficiency, subject scheduling/tracking, project management, and accrual/study performance. The outcome of these efforts resulted in rapid enrollment and study completion in a short time. The lessons learned from this experience can be used by other clinical trial sites faced with similar challenges.
- Published
- 2022
6. Small Cell Lung Cancer, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology.
- Author
-
Ganti, Apar Kishor P, Loo, Billy W, Bassetti, Michael, Blakely, Collin, Chiang, Anne, D'Amico, Thomas A, D'Avella, Christopher, Dowlati, Afshin, Downey, Robert J, Edelman, Martin, Florsheim, Charles, Gold, Kathryn A, Goldman, Jonathan W, Grecula, John C, Hann, Christine, Iams, Wade, Iyengar, Puneeth, Kelly, Karen, Khalil, Maya, Koczywas, Marianna, Merritt, Robert E, Mohindra, Nisha, Molina, Julian, Moran, Cesar, Pokharel, Saraswati, Puri, Sonam, Qin, Angel, Rusthoven, Chad, Sands, Jacob, Santana-Davila, Rafael, Shafique, Michael, Waqar, Saiama N, Gregory, Kristina M, and Hughes, Miranda
- Subjects
Clinical Research ,Cancer ,Rare Diseases ,Lung ,Lung Cancer ,Good Health and Well Being ,Humans ,Lung Neoplasms ,Medical Oncology ,Neoplasm Recurrence ,Local ,Small Cell Lung Carcinoma ,Oncology & Carcinogenesis - Abstract
The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Small Cell Lung Cancer (SCLC) provide recommended management for patients with SCLC, including diagnosis, primary treatment, surveillance for relapse, and subsequent treatment. This selection for the journal focuses on metastatic (known as extensive-stage) SCLC, which is more common than limited-stage SCLC. Systemic therapy alone can palliate symptoms and prolong survival in most patients with extensive-stage disease. Smoking cessation counseling and intervention should be strongly promoted in patients with SCLC and other high-grade neuroendocrine carcinomas. The "Summary of the Guidelines Updates" section in the SCLC algorithm outlines the most recent revisions for the 2022 update, which are described in greater detail in this revised Discussion text.
- Published
- 2021
7. Scirrhous carcinoma: A previously undescribed tumor of the oral cavity.
- Author
-
DeVries, Jacquelyn, Finegersh, Andrey, Gold, Kathryn A, Sharabi, Andrew B, Hu, Jingjing, and Orosco, Ryan K
- Subjects
adenocarcinoma ,operative chemoradiation ,scirrhous carcinoma ,surgical procedures - Abstract
This patient was found to have a scirrhous carcinoma with extensive perineural invasion and without any evidence of minor salivary gland carcinoma. To our knowledge, this is the first report of isolated scirrhous carcinoma of the oral cavity. Treatment was surgery and adjuvant chemoradiation, and there was complete disease response.
- Published
- 2021
8. Planning for post-pandemic cancer care delivery: Recovery or opportunity for redesign?
- Author
-
Cinar, Pelin, Bold, Richard, Bosslet, Bryn A, Bota, Daniela A, Burgess, Debra, Chew, Helen K, Cohen, Joshua G, Elquza, Emad, Gold, Kathryn A, Kamiya, Emi, Karlan, Beth Y, McKay, Rana R, Patel, Sandip P, Ternavan, Kimberly, Welborn, Jeanna, Yamamoto, Maki, and Rugo, Hope S
- Subjects
Humans ,Neoplasms ,Telemedicine ,Infection Control ,Cancer Care Facilities ,Delivery of Health Care ,California ,Pandemics ,Global Health ,COVID-19 ,COVID-19 Testing ,cancer care delivery ,coronavirus disease 2019 ,health care delivery ,pandemics ,Cancer ,Good Health and Well Being ,Clinical Sciences ,Public Health and Health Services ,Oncology & Carcinogenesis - Abstract
The delivery of cancer care has never changed as rapidly and dramatically as we have seen with the coronavirus disease 2019 (COVID-19) pandemic. During the early phase of the pandemic, recommendations for the management of oncology patients issued by various professional societies and government agencies did not recognize the significant regional differences in the impact of the pandemic. California initially experienced lower than expected numbers of cases, and the health care system did not experience the same degree of the burden that had been the case in other parts of the country. In light of promising trends in COVID-19 infections and mortality in California, by late April 2020, discussions were initiated for a phased recovery of full-scale cancer services. However, by July 2020, a surge of cases was reported across the nation, including in California. In this review, the authors share the response and recovery planning experience of the University of California (UC) Cancer Consortium in an effort to provide guidance to oncology practices. The UC Cancer Consortium was established in 2017 to bring together 5 UC Comprehensive Cancer Centers: UC Davis Comprehensive Cancer Center, UC Los Angeles Jonsson Comprehensive Cancer Center, UC Irvine Chao Family Comprehensive Cancer Center, UC San Diego Moores Cancer Center, and the UC San Francisco Helen Diller Family Comprehensive Cancer Center. The interventions implemented in each of these cancer centers are highlighted, with a focus on opportunities for a redesign in care delivery models. The authors propose that their experiences gained during this pandemic will enhance pre-pandemic cancer care delivery.
- Published
- 2021
9. Safety and Efficacy of Pembrolizumab With Chemoradiotherapy in Locally Advanced Head and Neck Squamous Cell Carcinoma: A Phase IB Study.
- Author
-
Powell, Steven F, Gold, Kathryn A, Gitau, Mark M, Sumey, Christopher J, Lohr, Michele M, McGraw, Steven C, Nowak, Ryan K, Jensen, Ashley W, Blanchard, Miran J, Fischer, Christopher D, Bykowski, Julie, Ellison, Christie A, Black, Lora J, Thompson, Paul A, Callejas-Valera, Juan L, Lee, John H, Cohen, Ezra EW, and Spanos, William C
- Subjects
Biomedical and Clinical Sciences ,Clinical Sciences ,Oncology and Carcinogenesis ,Immunology ,Infectious Diseases ,Dental/Oral and Craniofacial Disease ,Rare Diseases ,Cancer ,Sexually Transmitted Infections ,Clinical Research ,Evaluation of treatments and therapeutic interventions ,6.1 Pharmaceuticals ,Adult ,Aged ,Aged ,80 and over ,Antibodies ,Monoclonal ,Humanized ,Antineoplastic Agents ,Immunological ,Chemoradiotherapy ,Female ,Humans ,Male ,Middle Aged ,Retrospective Studies ,Squamous Cell Carcinoma of Head and Neck ,Oncology & Carcinogenesis ,Oncology and carcinogenesis - Abstract
PurposePembrolizumab is a humanized monoclonal antibody that blocks interaction between programmed death receptor-1 (PD-1) and its ligands (PD-L1, PD-L2). Although pembrolizumab is approved for recurrent/metastatic head and neck squamous cell carcinoma (HNSCC), its role in the management of locally advanced (LA) disease is not defined. We report a phase IB study evaluating the safety and efficacy of adding pembrolizumab to cisplatin-based chemoradiotherapy in patients with LA HNSCC.Patients and methodsEligible patients included those with oral cavity (excluding lip), oropharyngeal, hypopharyngeal, or laryngeal stage III to IVB HNSCC (according to American Joint Committee on Cancer, 7th edition, staging system) eligible for cisplatin-based, standard-dose (70 Gy) chemoradiotherapy. Pembrolizumab was administered concurrently with and after chemoradiotherapy with weekly cisplatin. Safety was the primary end point and was determined by incidence of chemoradiotherapy adverse events (AEs) and immune-related AEs (irAEs). Efficacy was defined as complete response (CR) rate on end-of-treatment (EOT) imaging or with pathologic confirmation at 100 days postradiotherapy completion. Key secondary end points included overall (OS) and progression-free survival (PFS).ResultsThe study accrued 59 patients (human papillomavirus [HPV] positive, n = 34; HPV negative, n = 25) from November 2015 to October 2018. Five patients (8.8%) required discontinuation of pembrolizumab because of irAEs, all of which occurred during concurrent chemoradiotherapy; 98.3% of patients completed the full planned treatment dose (70 Gy) of radiotherapy without any delays ≥ 5 days; 88.1% of patients completed the goal cisplatin dose of ≥ 200 mg/m2. EOT CR rates were 85.3% and 78.3% for those with HPV-positive and -negative HNSCC, respectively.ConclusionPembrolizumab in combination with weekly cisplatin-based chemoradiotherapy is safe and does not impair delivery of curative radiotherapy or chemotherapy in HNSCC. Early efficacy data support further investigation of this approach.
- Published
- 2020
10. Rapid onset type 1 diabetes with anti-PD-1 directed therapy
- Author
-
Yun, Karen, Daniels, Gregory, Gold, Kathryn, Mccowen, Karen, and Patel, Sandip Pravin
- Subjects
Prevention ,Autoimmune Disease ,Diabetes ,5.1 Pharmaceuticals ,Development of treatments and therapeutic interventions ,Metabolic and endocrine ,Good Health and Well Being ,PD-1 inhibitors ,diabetic ketoacidosis ,immune-related adverse event ,immunotherapy ,type 1 diabetes ,Oncology and Carcinogenesis - Abstract
Type 1 diabetes is a rare immune-related adverse event (irAE) caused by checkpoint inhibitors with serious risk for diabetic ketoacidosis (DKA). Using our electronic medical record, we identified 1327 adult patients who received PD-(L)1 or CTLA-4 inhibitors from 2013 to 2018. Of the patients who received immunotherapy, 5 (0.38%) patients were found to have type 1 diabetes, all of whom presented with DKA requiring insulin at 20 to 972 days from their first anti-PD-(L)1 dose. All patients were treated with anti-PD-1 therapy (nivolumab or pembrolizumab). Four patients had new onset diabetes with mean HbA1c of 9.1% on DKA presentation and persistent elevations over time. Two patients who tested positive for glutamic acid decarboxylase (GAD) antibodies presented with DKA at 20 and 106 days from first anti-PD-1 administration whereas patients who were autoantibody negative had DKA more than a year later. Type 1 diabetes occurs within a wide time frame after anti-PD-1 initiation and commences with an abrupt course. Our case series suggests that monitoring glycemia in patients on PD-1 inhibitors is not predictive for diabetes occurrence. GAD autoantibodies could portend earlier onset for diabetes, although further prospective studies are needed to elucidate their diagnostic utility and contribution in therapeutic interception.
- Published
- 2020
11. Circulating Tumor DNA Profiling in Small-Cell Lung Cancer Identifies Potentially Targetable Alterations
- Author
-
Devarakonda, Siddhartha, Sankararaman, Sumithra, Herzog, Brett H, Gold, Kathryn A, Waqar, Saiama N, Ward, Jeffrey P, Raymond, Victoria M, Lanman, Richard B, Chaudhuri, Aadel A, Owonikoko, Taofeek K, Li, Bob T, Poirier, John T, Rudin, Charles M, Govindan, Ramaswamy, and Morgensztern, Daniel
- Subjects
Biomedical and Clinical Sciences ,Clinical Sciences ,Oncology and Carcinogenesis ,Genetics ,Clinical Research ,Cancer ,Human Genome ,Detection ,screening and diagnosis ,4.1 Discovery and preclinical testing of markers and technologies ,Good Health and Well Being ,Adult ,Aged ,Aged ,80 and over ,Antineoplastic Agents ,Biomarkers ,Tumor ,Circulating Tumor DNA ,DNA Repair ,DNA-Binding Proteins ,Feasibility Studies ,Female ,High-Throughput Nucleotide Sequencing ,Humans ,Liquid Biopsy ,Lung Neoplasms ,Male ,Middle Aged ,Mutation ,Neoplasm Recurrence ,Local ,Prospective Studies ,Proto-Oncogene Proteins c-myc ,Small Cell Lung Carcinoma ,Transcription Factors ,Young Adult ,Oncology & Carcinogenesis ,Clinical sciences ,Oncology and carcinogenesis - Abstract
PurposePatients with SCLC rarely undergo biopsies at relapse. When pursued, tissue obtained can be inadequate for molecular testing, posing a challenge in identifying potentially targetable alterations in a clinically meaningful time frame. We examined the feasibility of circulating tumor DNA (ctDNA) testing in identifying potentially targetable alterations in SCLC.Experimental designctDNA test results were prospectively collected from patients with SCLC between 2014 and 2017 and analyzed. ctDNA profiles of SCLC at diagnosis and relapse were also compared.ResultsA total of 609 samples collected from 564 patients between 2014 and 2017 were analyzed. The median turnaround time for test results was 14 days. Among patients with data on treatment status, there were 61 samples from 59 patients and 219 samples from 206 patients collected at diagnosis and relapse, respectively. The number of mutations or amplifications detected per sample did not differ by treatment status. Potentially targetable alterations in DNA repair, MAPK and PI3K pathways, and genes such as MYC and ARID1A were identifiable through ctDNA testing. Furthermore, our results support that it may be possible to reconstruct the clonal relationship between detected variants through ctDNA testing.ConclusionsPatients with relapsed SCLC rarely undergo biopsies for molecular testing and often require prompt treatment initiation. ctDNA testing is less invasive and capable of identifying alterations in relapsed disease in a clinically meaningful timeframe. ctDNA testing on an expanded gene panel has the potential to advance our knowledge of the mechanisms underlying treatment resistance in SCLC and aid in the development of novel treatment strategies.
- Published
- 2019
12. Immune Modulation of Head and Neck Squamous Cell Carcinoma and the Tumor Microenvironment by Conventional Therapeutics.
- Author
-
Miyauchi, Sayuri, Kim, Sangwoo S, Pang, John, Gold, Kathryn A, Gutkind, J Silvio, Califano, Joseph A, Mell, Loren K, Cohen, Ezra EW, and Sharabi, Andrew B
- Subjects
Animals ,Humans ,Head and Neck Neoplasms ,Immunotherapy ,Combined Modality Therapy ,Immunomodulation ,Tumor Microenvironment ,Squamous Cell Carcinoma of Head and Neck ,Oncology And Carcinogenesis ,Oncology & Carcinogenesis ,Oncology and Carcinogenesis - Abstract
Head and neck squamous cell carcinoma (HNSCC) accounts for more than 600,000 cases and 380,000 deaths annually worldwide. Although human papillomavirus (HPV)-associated HNSCCs have better overall survival compared with HPV-negative HNSCC, loco-regional recurrence remains a significant cause of mortality and additional combinatorial strategies are needed to improve outcomes. The primary conventional therapies to treat HNSCC are surgery, radiation, and chemotherapies; however, multiple other targeted systemic options are used and being tested including cetuximab, bevacizumab, mTOR inhibitors, and metformin. In 2016, the first checkpoint blockade immunotherapy was approved for recurrent or metastatic HNSCC refractory to platinum-based chemotherapy. This immunotherapy approval confirmed the critical importance of the immune system and immunomodulation in HNSCC pathogenesis, response to treatment, and disease control. However, although immuno-oncology agents are rapidly expanding, the role that the immune system plays in the mechanism of action and clinical efficacy of standard conventional therapies is likely underappreciated. In this article, we focus on how conventional and targeted therapies may directly modulate the immune system and the tumor microenvironment to better understand the effects and combinatorial potential of these therapies in the context and era of immunotherapy.
- Published
- 2019
13. Erlotinib in the treatment of recurrent or metastatic cutaneous squamous cell carcinoma: A single‐arm phase 2 clinical trial
- Author
-
Gold, Kathryn A, Kies, Merrill S, William, William N, Johnson, Faye M, Lee, J Jack, and Glisson, Bonnie S
- Subjects
Biomedical and Clinical Sciences ,Clinical Sciences ,Oncology and Carcinogenesis ,Cancer ,Clinical Research ,Clinical Trials and Supportive Activities ,Rare Diseases ,6.2 Cellular and gene therapies ,6.1 Pharmaceuticals ,Evaluation of treatments and therapeutic interventions ,Aged ,Aged ,80 and over ,Carcinoma ,Squamous Cell ,Disease Progression ,ErbB Receptors ,Erlotinib Hydrochloride ,Feasibility Studies ,Female ,Humans ,Male ,Middle Aged ,Neoplasm Recurrence ,Local ,Protein Kinase Inhibitors ,Response Evaluation Criteria in Solid Tumors ,Skin Neoplasms ,squamous cell carcinoma ,skin cancer ,erlotinib ,epidermal growth factor receptor ,anti-neoplastic agents ,Public Health and Health Services ,Oncology & Carcinogenesis ,Oncology and carcinogenesis ,Public health - Abstract
BACKGROUND:Cutaneous squamous cell carcinoma (CSCC) is a very common malignancy in which most patients present with localized disease. Recurrent and metastatic disease is rare, and there is no standard therapy. These tumors frequently overexpress the epidermal growth factor receptor (EGFR). We conducted a phase 2 trial to determine the response rate to therapy with erlotinib, an EGFR tyrosine kinase inhibitor, in patients with locoregionally recurrent or metastatic CSCC that was not amenable to curative treatment (NCT01198028). METHODS:Eligible patients had CSCC not amenable to curative intent therapy. Patients who had previously received anti-EGFR targeted therapy were excluded. All patients received oral therapy with erlotinib 150 mg daily. Response was assessed every 8 weeks, and treatment continued until progression, unacceptable toxicity, or withdrawal of consent. The primary endpoint was overall response rate according to RECIST 1.1 criteria. RESULTS:A total of 39 patients received treatment during the trial; 29 of these patients were evaluable for response. The overall response rate was 10% (3/29); all responses were partial responses. The disease control rate (partial response + stable disease) was 72% (21/29). The median progression-free survival was 4.7 months (95% confidence interval, 3.5-6.2 months); the median overall survival was 13 months (95% confidence interval, 8.4-20.5 months). No unexpected toxicities were seen. CONCLUSION:Erlotinib therapy was feasible for most patients with incurable CSCC and was associated with expected toxicities. However, only a modest response rate of 10% was observed. Further study of EGFR tyrosine kinase inhibitors in this patient population is not warranted. Cancer 2018;124:2169-73. © 2018 American Cancer Society.
- Published
- 2018
14. Induction Cisplatin Docetaxel Followed by Surgery and Erlotinib in Non-Small Cell Lung Cancer
- Author
-
Cascone, Tina, Gold, Kathryn A, Swisher, Stephen G, Liu, Diane D, Fossella, Frank V, Sepesi, Boris, Pataer, Apar, Weissferdt, Annikka, Kalhor, Neda, Vaporciyan, Ara A, Hofstetter, Wayne L, Wistuba, Ignacio I, Heymach, John V, Kim, Edward S, and William, William N
- Subjects
Biomedical and Clinical Sciences ,Clinical Sciences ,Oncology and Carcinogenesis ,Cancer ,Rare Diseases ,Patient Safety ,Lung ,Lung Cancer ,6.1 Pharmaceuticals ,Evaluation of treatments and therapeutic interventions ,Adult ,Aged ,Aged ,80 and over ,Antineoplastic Agents ,Carcinoma ,Non-Small-Cell Lung ,Chemotherapy ,Adjuvant ,Cisplatin ,Docetaxel ,Dose-Response Relationship ,Drug ,Drug Therapy ,Combination ,Erlotinib Hydrochloride ,Female ,Follow-Up Studies ,Humans ,Induction Chemotherapy ,Lung Neoplasms ,Male ,Middle Aged ,Neoplasm Staging ,Pneumonectomy ,Postoperative Care ,Retrospective Studies ,Taxoids ,Time Factors ,Treatment Outcome ,Cardiorespiratory Medicine and Haematology ,Respiratory System ,Cardiovascular medicine and haematology ,Clinical sciences - Abstract
BackgroundData from meta-analyses support the use of induction or adjuvant platinum-based chemotherapy for locally advanced non-small cell lung cancers (NSCLCs). This phase 2 study assessed the role of induction cisplatin and docetaxel followed by surgery in patients with resectable stage I to III NSCLCs, followed by 12 months of adjuvant erlotinib.MethodsPatients with resectable stage I to III NSCLCs received cisplatin 80 mg/m2, docetaxel 75 mg/m2 every 21 days for 3 cycles, followed by surgery, followed by adjuvant erlotinib for 12 months. The primary endpoint included safety. Long-term efficacy outcomes and exploratory analysis of intermediary endpoints are also reported (NCT00254384).ResultsForty-seven eligible patients received a median of 3 cycles of induction treatment, 37 underwent surgical resection, and only 21 received adjuvant erlotinib. Two patients died in the perioperative period (1 sepsis during chemotherapy, 1 acute respiratory distress syndrome postoperatively). Most common grade 3 to 5 toxicities during chemotherapy included hypokalemia (8%), infection (7%), and granulocytopenia (25%). During adjuvant erlotinib, 14% of patients experienced grade 2 rash. Median overall survival was 3.4 years. Major pathologic responses in the primary tumor were observed in 19% (7 of 37) of patients and correlated with improved long-term overall survival. Complete pathologic response in mediastinal/hilar nodes also correlated with superior survival.ConclusionsInduction cisplatin and docetaxel was well tolerated. Adjuvant erlotinib did not improve outcomes compared with historical controls. Major pathologic response predicted for improved long-term survival and is a suitable intermediary endpoint for future phase 2 studies.
- Published
- 2018
15. The Influence of Body Mass Index on Overall Survival Following Surgical Resection of Non–Small Cell Lung Cancer
- Author
-
Sepesi, Boris, Gold, Kathryn A, Correa, Arlene M, Heymach, John V, Vaporciyan, Ara A, Roszik, Jason, Dmitrovsky, Ethan, and Liu, Xi
- Subjects
Biomedical and Clinical Sciences ,Oncology and Carcinogenesis ,Prevention ,Lung ,Patient Safety ,Cancer ,Lung Cancer ,Clinical Research ,Obesity ,Adolescent ,Adult ,Aged ,Aged ,80 and over ,Body Mass Index ,Carcinoma ,Non-Small-Cell Lung ,Female ,Humans ,Lung Neoplasms ,Male ,Middle Aged ,Survival Analysis ,Young Adult ,BMI ,Lung cancer ,Overall survival ,Cardiorespiratory Medicine and Haematology ,Clinical Sciences ,Oncology & Carcinogenesis ,Clinical sciences ,Oncology and carcinogenesis - Abstract
BackgroundPopulation studies suggest that high body mass index (BMI) correlates with a reduced risk for death from lung cancer. The aim of our study was to evaluate definitively the influence of BMI on long-term overall survival (OS) in surgical patients with NSCLC.MethodsThe study population consisted of 1935 patients who underwent surgical resection for lung cancer at M. D. Anderson Cancer Center (2000-2014). Study variables included both patient- and treatment-related characteristics. Univariate and multivariate Cox regression analyses were performed to identify variables associated with OS.ResultsOn univariate analysis, significant predictors of improved survival were higher BMI, pathologic tumor stage (stage I versus stage II, III, or IV), type of surgical procedure (lobectomy/pneumonectomy versus wedge resection/segmentectomy), younger age, female sex, and adenocarcinoma histologic subtype (versus squamous) (all p < 0.05). Morbidly obese patients (BMI ≥ 35) demonstrated a trend toward better outcomes than those classified as obese (BMI ≥30 and
- Published
- 2017
16. Sleep and Breathing … and Cancer?
- Author
-
Owens, Robert L, Gold, Kathryn A, Gozal, David, Peppard, Paul E, Jun, Jonathan C, Dannenberg, Andrew J, Lippman, Scott M, and Malhotra, Atul
- Subjects
Biomedical and Clinical Sciences ,Medical Physiology ,Cardiovascular Medicine and Haematology ,Sleep Research ,Neurosciences ,Behavioral and Social Science ,Cancer ,Clinical Research ,Lung ,Basic Behavioral and Social Science ,Animals ,Humans ,Neoplasms ,Sleep ,Sleep Apnea ,Obstructive ,UCSD Sleep and Cancer Symposium Group ,Clinical Sciences ,Oncology and Carcinogenesis ,Oncology & Carcinogenesis ,Clinical sciences ,Oncology and carcinogenesis - Abstract
Sleep, like eating and breathing, is an essential part of the daily life cycle. Although the science is still emerging, sleep plays an important role in immune, cardiovascular, and neurocognitive function. Despite its great importance, nearly 40% of U.S. adults experience problems with sleep ranging from insufficient total sleep time, trouble initiating or maintaining sleep (Insomnia), circadian rhythm disorders, sleep-related movement disorders, and sleep-related breathing disorders such as obstructive sleep apnea (OSA). Herein, we discuss new evidence that suggests that sleep may also affect carcinogenesis. Specifically, we review recent epidemiologic data suggesting links between cancer and OSA. As OSA is a common, underdiagnosed, and undertreated condition, this has public health implications. Intriguing animal model data support a link between cancer and sleep/OSA, although mechanisms are not yet clear. Leaders in the fields of sleep medicine, pulmonology, and oncology recently met to review and discuss these data, as well as to outline future directions of study. We propose a multidisciplinary, three-pronged approach to studying the associations between cancer and sleep, utilizing mutually interactive epidemiologic studies, preclinical models, and early-phase clinical trials. Cancer Prev Res; 9(11); 821-7. ©2016 AACR.
- Published
- 2016
17. Alectinib in ALK-positive, crizotinib-resistant, non-small-cell lung cancer: a single-group, multicentre, phase 2 trial
- Author
-
Shaw, Alice T, Gandhi, Leena, Gadgeel, Shirish, Riely, Gregory J, Cetnar, Jeremy, West, Howard, Camidge, D Ross, Socinski, Mark A, Chiappori, Alberto, Mekhail, Tarek, Chao, Bo H, Borghaei, Hossein, Gold, Kathryn A, Zeaiter, Ali, Bordogna, Walter, Balas, Bogdana, Puig, Oscar, Henschel, Volkmar, and Ou, Sai-Hong Ignatius
- Published
- 2016
18. Modulation of Biomarker Expression by Osimertinib: Results of the Paired Tumor Biopsy Cohorts of the AURA Phase I Trial
- Author
-
Thress, Kenneth S., Jacobs, Vivien, Angell, Helen K., Yang, James Chih-Hsin, Sequist, Lecia V., Blackhall, Fiona, Su, Wu-Chou, Schuler, Martin, Wolf, Jürgen, Gold, Kathryn A., Cantarini, Mireille, Barrett, Carl J., and Jänne, Pasi A.
- Published
- 2017
- Full Text
- View/download PDF
19. Efficacy and Safety of Patritumab Deruxtecan (HER3-DXd) in EGFR Inhibitor-Resistant, EGFR-Mutated Non-Small Cell Lung Cancer
- Author
-
Jänne, Pasi A, Baik, Christina, Su, Wu-Chou, Johnson, Melissa L, Hayashi, Hidetoshi, Nishio, Makoto, Kim, Dong-Wan, Koczywas, Marianna, Gold, Kathryn A, Steuer, Conor E, Murakami, Haruyasu, Yang, James Chih-Hsin, Kim, Sang-We, Vigliotti, Michele, Shi, Rong, Qi, Zhenhao, Qiu, Yang, Zhao, Lihui, Sternberg, David, Yu, Channing, and Yu, Helena A
- Subjects
Male ,Infusions ,Lung Neoplasms ,Oncology and Carcinogenesis ,Antineoplastic Agents ,Disease-Free Survival ,Antibodies ,Dose-Response Relationship ,Clinical Research ,Monoclonal ,Humans ,Neoplasm Metastasis ,Non-Small-Cell Lung ,Humanized ,Lung ,Aged ,Cancer ,Carcinoma ,Lung Cancer ,Evaluation of treatments and therapeutic interventions ,Middle Aged ,ErbB Receptors ,Treatment Outcome ,Immunological ,5.1 Pharmaceuticals ,6.1 Pharmaceuticals ,Camptothecin ,Female ,Drug ,Development of treatments and therapeutic interventions ,Intravenous - Abstract
Receptor tyrosine-protein kinase ERBB3 (HER3) is expressed in most EGFR-mutated lung cancers but is not a known mechanism of resistance to EGFR inhibitors. HER3-DXd is an antibody-drug conjugate consisting of a HER3 antibody attached to a topoisomerase I inhibitor payload via a tetrapeptide-based cleavable linker. This phase I, dose escalation/expansion study included patients with locally advanced or metastatic EGFR-mutated non-small cell lung cancer (NSCLC) with prior EGFR tyrosine kinase inhibitor (TKI) therapy. Among 57 patients receiving HER3-DXd 5.6 mg/kg intravenously once every 3 weeks, the confirmed objective response rate by blinded independent central review (Response Evaluation Criteria in Solid Tumors v1.1) was 39% [95% confidence interval (CI), 26.0-52.4], and median progression-free survival was 8.2 (95% CI, 4.4-8.3) months. Responses were observed in patients with known and unknown EGFR TKI resistance mechanisms. Clinical activity was observed across a broad range of HER3 membrane expression. The most common grade ≥3 treatment-emergent adverse events were hematologic toxicities. HER3-DXd has clinical activity in EGFR TKI-resistant cancers independent of resistance mechanisms, providing an approach to treat a broad range of drug-resistant cancers. SIGNIFICANCE: In metastatic EGFR-mutated NSCLC, after disease progression on EGFR TKI therapy, treatment approaches include genotype-directed therapy targeting a known resistance mechanism or chemotherapy. HER3-DXd demonstrated clinical activity spanning known and unknown EGFR TKI resistance mechanisms. HER3-DXd could present a future treatment option agnostic to the EGFR TKI resistance mechanism.See related commentary by Lim et al., p. 16.This article is highlighted in the In This Issue feature, p. 1.
- Published
- 2022
20. Comparison of Early- and Late-Stage Breast and Colorectal Cancer Diagnoses During vs Before the COVID-19 Pandemic
- Author
-
Zhou, Jade Zifei, primary, Kane, Shelly, additional, Ramsey, Celia, additional, Akhondzadeh, Melody, additional, Banerjee, Ananya, additional, Shatsky, Rebecca, additional, and Gold, Kathryn Ann, additional
- Published
- 2022
- Full Text
- View/download PDF
21. Abstract CT134: A phase I study of avelumab, palbociclib, and cetuximab (APC) in recurrent or metastatic head and neck squamous cell carcinoma (RM HNSCC)
- Author
-
Gold, Kathryn A., primary, Sacco, Assuntina, additional, Bykowski, Julie, additional, Daniels, Gregory, additional, Pittman, Emily, additional, Messer, Karen, additional, Chen, Ruifeng, additional, and Cohen, Ezra, additional
- Published
- 2021
- Full Text
- View/download PDF
22. MO30-5 Updated efficacy and safety of patritumab deruxtecan (HER3-DXd; U3-1402), a HER3 directed antibody drug conjugate, in EGFRm NSCLC
- Author
-
Hayashi, Hidetoshi, primary, Yu, Helena A., additional, Baik, Christina, additional, Gold, Kathryn, additional, Johnson, Melissa L., additional, Koczywas, Marianna, additional, Murakami, Haruyasu, additional, Nishio, Makoto, additional, Steuer, Conor, additional, Su, Wu-Chou, additional, Yang, James C.H., additional, Karam, Samer, additional, Qui, Zhenhao, additional, Qiu, Yang, additional, Chen, Shuquan, additional, Yu, Channing, additional, and Janne, Pasi A., additional
- Published
- 2021
- Full Text
- View/download PDF
23. FDG-PET/CT as a Predictor of Outcome in EGFR-Mutant Non–Small-Cell Lung Cancer
- Author
-
Gold, Kathryn A. and Erasmus, Jeremy J.
- Published
- 2015
- Full Text
- View/download PDF
24. Relationship Between Tumor Size and Survival in Non–Small-Cell Lung Cancer (NSCLC): An Analysis of the Surveillance, Epidemiology, and End Results (SEER) Registry
- Author
-
Zhang, Jianjun, Gold, Kathryn A., Lin, Heather Y., Swisher, Stephen G., Xing, Yan, Lee, J. Jack, Kim, Edward S., and William, William N., Jr.
- Published
- 2015
- Full Text
- View/download PDF
25. Selective Antitumor Activity of Ibrutinib in EGFR-Mutant Non-Small Cell Lung Cancer Cells
- Author
-
Gao, Wen, Wang, Michael, Wang, Li, Lu, Haibo, Wu, Shuhong, Dai, Bingbing, Ou, Zhishuo, Zhang, Liang, Heymach, John V., Gold, Kathryn A., Minna, John, Roth, Jack A., Hofstetter, Wayne L., Swisher, Stephen G., and Fang, Bingliang
- Published
- 2014
- Full Text
- View/download PDF
26. Computed Tomography RECIST Assessment of Histopathologic Response and Prediction of Survival in Patients with Resectable Non–Small-Cell Lung Cancer after Neoadjuvant Chemotherapy
- Author
-
William, William N., Jr, Pataer, Apar, Kalhor, Neda, Correa, Arlene M., Rice, David C., Wistuba, Ignacio I., Heymach, John, Lee, J. Jack, Kim, Edward S., Munden, Reginald, Gold, Kathryn A., Papadimitrakopoulou, Vassiliki, Swisher, Stephen G., and Erasmus, Jeremy J.
- Published
- 2013
- Full Text
- View/download PDF
27. Planning for post‐pandemic cancer care delivery: Recovery or opportunity for redesign?
- Author
-
Cinar, Pelin, primary, Bold, Richard, additional, Bosslet, Bryn A., additional, Bota, Daniela A., additional, Burgess, Debra, additional, Chew, Helen K., additional, Cohen, Joshua G., additional, Elquza, Emad, additional, Gold, Kathryn A., additional, Kamiya, Emi, additional, Karlan, Beth Y., additional, McKay, Rana R., additional, Patel, Sandip P., additional, Ternavan, Kimberly, additional, Welborn, Jeanna, additional, Yamamoto, Maki, additional, and Rugo, Hope S., additional
- Published
- 2020
- Full Text
- View/download PDF
28. MtsR is a dual regulator that controls virulence genes and metabolic functions in addition to metal homeostasis in the group A streptococcus
- Author
-
Toukoki, Chadia, Gold, Kathryn M., McIver, Kevin S., and Eichenbaum, Zehava
- Published
- 2010
- Full Text
- View/download PDF
29. Abstract 5734: The influence of body mass index on overall survival following surgical resection of non-small cell lung cancer
- Author
-
Liu, Xi, primary, Sepesi, Boris, additional, Gold, Kathryn A., additional, Correa, Arlene M., additional, Heymach, John V., additional, Vaporciyan, Ara A., additional, Roszik, Jason, additional, and Dmitrovsky, Ethan, additional
- Published
- 2017
- Full Text
- View/download PDF
30. MA14.03 The Impact of Genomic Landscape of EGFR Mutant NSCLC on Response to Targeted and Immune Therapy
- Author
-
Elamin, Yasir, primary, Rinsurongkawong, Waree, additional, Tran, Hai, additional, Gold, Kathryn, additional, Lewis, Jeff, additional, Roarty, Emily, additional, Futreal, Andrew, additional, Zhang, Jianjun, additional, and Heymach, John, additional
- Published
- 2017
- Full Text
- View/download PDF
31. MA04.02 Neratinib ± Temsirolimus in HER2-Mutant Lung Cancers: An International, Randomized Phase II Study
- Author
-
Gandhi, Leena, primary, Besse, Benjamin, additional, Mazieres, Julien, additional, Waqar, Saiama, additional, Cortot, Alexis, additional, Barlesi, Fabrice, additional, Quoix, Elisabeth, additional, Otterson, Gregory, additional, Ettinger, David, additional, Horn, Leora, additional, Moro-Sibilot, Denis, additional, Socinski, Mark, additional, Gold, Kathryn, additional, Gray, Jhanelle, additional, Oton, Ana, additional, Heist, Rebecca Suk, additional, Costa, Daniel, additional, Mcculloch, Leanne, additional, Bebchuk, Judith, additional, Bryce, Richard, additional, and Kris, Mark, additional
- Published
- 2017
- Full Text
- View/download PDF
32. OA08.06 Brigatinib Activity in Patients with ALK+ NSCLC and Intracranial CNS Metastases in Two Clinical Trials
- Author
-
Gettinger, Scott, primary, Kim, Dong-Wan, additional, Tiseo, Marcello, additional, Langer, Corey, additional, Ahn, Myung-Ju, additional, Shaw, Alice, additional, Huber, Rudolf, additional, Hochmair, Maximilian, additional, Kim, Sang-We, additional, Bazhenova, Lyudmila, additional, Gold, Kathryn, additional, Ou, Sai-Hong, additional, West, Howard, additional, Reichmann, William, additional, Haney, Jeff, additional, Clackson, Tim, additional, Haluska, Frank, additional, Kerstein, David, additional, and Camidge, D. Ross, additional
- Published
- 2017
- Full Text
- View/download PDF
33. MA07.02 Updated Efficacy and Safety Data from the Phase 2 NP28761 Study of Alectinib in ALK-Positive Non-Small-Cell Lung Cancer
- Author
-
Camidge, D. Ross, primary, Gadgeel, Shirish, additional, Ou, Sai-Hong, additional, Gandhi, Leena, additional, Riely, Gregory, additional, Cetnar, Jeremy, additional, West, Howard, additional, Socinski, Mark, additional, Chiappori, Alberto, additional, Mekhail, Tarek, additional, Chao, Bo, additional, Borghaei, Hossein, additional, Gold, Kathryn, additional, Bordogna, Walter, additional, Balas, Bogdana, additional, Noe, Johannes, additional, Golding, Sophie, additional, Zeaiter, Ali, additional, and Shaw, Alice, additional
- Published
- 2017
- Full Text
- View/download PDF
34. 31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): late breaking abstracts
- Author
-
Althammer, Sonja, primary, Steele, Keith, additional, Rebelatto, Marlon, additional, Tan, Tze Heng, additional, Wiestler, Tobias, additional, Schmidt, Guenter, additional, Higgs, Brandon, additional, Li, Xia, additional, Shi, Li, additional, Jin, Xiaoping, additional, Antal, Joyce, additional, Gupta, Ashok, additional, Ranade, Koustubh, additional, Binning, Gerd, additional, Bellmunt, Joaquim, additional, de Wit, Ronald, additional, Vaughn, David J., additional, Fradet, Yves, additional, Lee, Jae Lyun, additional, Fong, Lawrence, additional, Vogelzang, Nicholas J., additional, Climent, Miguel A., additional, Petrylak, Daniel P., additional, Choueiri, Toni K., additional, Necchi, Andrea, additional, Gerritsen, Winald, additional, Gurney, Howard, additional, Quinn, David I., additional, Culine, Stéphane, additional, Sternberg, Cora N., additional, Mai, Yabing, additional, Puhlmann, Markus, additional, Perini, Rodolfo F., additional, Bajorin, Dean F., additional, Sharma, Padmanee, additional, Callahan, Margaret K., additional, Calvo, Emiliano, additional, Kim, Joseph W., additional, de Braud, Filipo, additional, Ott, Patrick A., additional, Bono, Petri, additional, Pillai, Rathi N., additional, Morse, Michael, additional, Le, Dung T., additional, Taylor, Matthew, additional, Spilliopoulou, Pavlina, additional, Bendell, Johanna, additional, Jaeger, Dirk, additional, Chan, Emily, additional, Antonia, Scott J., additional, Ascierto, Paolo A., additional, Hennicken, Delphine, additional, Tschaika, Marina, additional, Azrilevich, Alex, additional, Rosenberg, Jonathan, additional, Levy, Ofer, additional, Chan, Christopher, additional, Cojocaru, Gady, additional, Liang, Spencer, additional, Ophir, Eran, additional, Ganguly, Sudipto, additional, Toporik, Amir, additional, Kotturi, Maya, additional, Kfir, Tal Fridman, additional, Murter, Benjamin M., additional, Logronio, Kathryn, additional, Dassa, Liat, additional, Leung, Ling, additional, Greenwald, Shirley, additional, Azulay, Meir, additional, Kumar, Sandeep, additional, Alteber, Zoya, additional, Pan, Xiaoyu, additional, Machlenkin, Arthur, additional, Benita, Yair, additional, Drake, Andrew W., additional, Chajut, Ayelet, additional, Salomon, Ran, additional, Vankin, Ilan, additional, Safyon, Einav, additional, Hunter, John, additional, Levine, Zurit, additional, White, Mark, additional, Leidner, Rom, additional, Kang, Hyunseok, additional, Haddad, Robert, additional, Segal, Neil H., additional, Wirth, Lori J., additional, Ferris, Robert L., additional, Hodi, F. Stephen, additional, Sanborn, Rachel E., additional, Gajewski, Thomas F., additional, Sharfman, William, additional, McDonald, Dan, additional, Srivastava, Shivani, additional, Gu, Xuemin, additional, Phillips, Penny, additional, Passey, Chaitali, additional, Seiwert, Tanguy, additional, Habtetsion, Tsadik, additional, Zhou, Gang, additional, Sakellariou-Thompson, Donastas, additional, Haymaker, Cara, additional, Creasy, Caitlin, additional, Hurd, Mark, additional, Uraoka, Naohiro, additional, Canales, Jaime Rodriguez, additional, Koptez, Scott, additional, Hwu, Patrick, additional, Maitra, Anirban, additional, Bernatchez, Chantale, additional, Coyle, Scott M., additional, Roybel, Kole T., additional, Rupp, Levi J., additional, Santoro, Stephen P., additional, Secrest, Stephanie, additional, Spelman, Michael, additional, Ho, Hanson, additional, Gomes, Tina, additional, Tse, Tiffany, additional, Yung-Wu, Chia, additional, Taunton, Jack, additional, Lim, Wendell, additional, Emtage, Peter, additional, Moudgil, Tarsem, additional, Ballesteros-Merino, Carmen, additional, Hilton, Traci, additional, Paustian, Christopher, additional, Page, David, additional, Urba, Walter, additional, Fox, Bernard, additional, Bell, Bryan, additional, Patel, Ashish, additional, Olafsen, Tove, additional, Satpayev, Daulet, additional, Torgov, Michael, additional, Marchioni, Filippo, additional, Romero, Jason, additional, Jiang, Ziyue Karen, additional, Zamilpa, Charles, additional, Keppler, Jennifer S., additional, Mascioni, Alessandro, additional, Jia, Fang, additional, Lee, Chen-Yu, additional, Gudas, Jean, additional, Sullivan, Ryan J., additional, Hoshida, Yujin, additional, Logan, Theodore, additional, Khushalani, Nikhil, additional, Giobbie-Hurder, Anita, additional, Margolin, Kim, additional, Roder, Joanna, additional, Bhatt, Rupal, additional, Koon, Henry, additional, Olencki, Thomas, additional, Hutson, Thomas, additional, Curti, Brendan, additional, Blackmon, Shauna, additional, Mier, James W., additional, Puzanov, Igor, additional, Roder, Heinrich, additional, Stewart, John, additional, Amin, Asim, additional, Ernstoff, Marc S., additional, Clark, Joseph I., additional, Atkins, Michael B., additional, Kaufman, Howard L., additional, Sosman, Jeffrey, additional, Signoretti, Sabina, additional, McDermott, David F., additional, Anderson, Abraham A., additional, Milhem, Mohammed M., additional, Andtbacka, Robert H. I., additional, Minor, David, additional, Gorski, Kevin S., additional, Baker, Daniel M., additional, Hamid, Omid, additional, Akporiaye, Emmanuel, additional, Koguchi, Yoshinobu, additional, Sutcliffe, Kim, additional, Conder, Kristie, additional, Marron, Thomas, additional, Bhardwaj, Nina, additional, Hammerich, Linda, additional, George, Fiby, additional, Kim-Schulze, Seunghee, additional, Keler, Tibor, additional, Davis, Tom, additional, Crowley, Elizabeth, additional, Salazar, Andres, additional, Brody, Joshua, additional, Monjazeb, Arta, additional, Daly, Megan E., additional, Riess, Jonathan, additional, Li, Tianhong, additional, Murphy, William J., additional, Kelly, Karen, additional, Hu, Zhiwei, additional, Shen, Rulong, additional, Campbell, Amanda, additional, McMichael, Elizabeth, additional, Yu, Lianbo, additional, Ramaswam, Bhuvaneswari, additional, London, Cheryl A., additional, Xu, Tian, additional, Carson, William, additional, Kokolus, Kathleen M., additional, Repasky, Elizabeth A., additional, Schell, Todd D., additional, Drabick, Joseph D., additional, Messenheimer, David J., additional, Jensen, Shawn, additional, Rubinstein, Mark, additional, Andrijauskaite, Kristina, additional, Swiderska-syn, Marzena, additional, Lind, Kristin, additional, Choppin, Agnes, additional, Roell, Marina K., additional, Wrangle, John, additional, Rhode, Peter, additional, Wong, Hing, additional, Ahmad, Shamim, additional, Webb, Mason, additional, Abu-Eid, Rasha, additional, Shrimali, Rajeev, additional, Verma, Vivek, additional, Doroodchi, Atbin, additional, Berrong, Zuzana, additional, Yashar, David, additional, Samara, Raed, additional, Mkrtichyan, Mikayel, additional, Khleif, Samir, additional, Powell, Steven, additional, Gitau, Mark, additional, Sumey, Christopher, additional, Terrell, Andrew, additional, Lohr, Michele, additional, Nowak, Ryan K., additional, McGraw, Steven, additional, Jensen, Ash, additional, Blanchard, Miran, additional, Gold, Kathryn A., additional, Cohen, Ezra E. W., additional, Ellison, Christie, additional, Black, Lora, additional, Lee, John, additional, Spanos, William Chad, additional, Wennerberg, Erik, additional, Schwitzer, Emily, additional, Lhuillier, Claire, additional, Koelwyn, Graeme, additional, Hiner, Rebecca, additional, Jones, Lee, additional, Demaria, Sandra, additional, Amanda, Vandeveer, additional, Greiner, John W., additional, Schlom, Jeffrey, additional, Bookstaver, Michelle, additional, Jewell, Christopher M., additional, Gunderson, Andrew, additional, Boulmay, Brian, additional, Li, Rui, additional, Spieler, Bradley, additional, Happel, Kyle, additional, Feng, Zipei, additional, Dubay, Christopher, additional, Fisher, Brenda, additional, Aung, Sandra, additional, Mederos, Eileen, additional, Bifulco, Carlo B., additional, McNamara, Michael, additional, Bahjat, Keith, additional, Redmond, William, additional, Ochoa, Augusto, additional, Hu, Hong-Ming, additional, Mehta, Adi, additional, Lund-Johansen, Fridtjof, additional, Bedu-Addo, Frank, additional, Conn, Greg, additional, King, Michael, additional, Dutta, Panna, additional, Shepard, Robert, additional, Einstein, Mark, additional, Adams, Sylvia, additional, Wang, Ena, additional, Jin, Ping, additional, Novik, Yelena, additional, Morrison, Debra, additional, Oratz, Ruth, additional, Marincola, Franco M., additional, Stroncek, David, additional, Goldberg, Judith, additional, Formenti, Silvia C., additional, Galon, Jérôme, additional, Mlecnik, Bernhard, additional, Marliot, Florence, additional, Ou, Fang-Shu, additional, Lugli, Alessandro, additional, Zlobec, Inti, additional, Rau, Tilman T., additional, Nagtegaal, Iris D., additional, Vink-Borger, Elisa, additional, Hartmann, Arndt, additional, Geppert, Carol, additional, Roehrl, Michael H., additional, Bavi, Prashant, additional, Ohashi, Pamela S., additional, Wang, Julia Y., additional, Nguyen, Linh T., additional, Han, SeongJun, additional, MacGregor, Heather L., additional, Hafezi-Bakhtiari, Sara, additional, Wouters, Bradley G., additional, Kawakami, Yutaka, additional, Papivanova, Boryana, additional, Xu, Mingli, additional, Fujita, Tomonobu, additional, Hazama, Shoichi, additional, Suzuki, Nobuaki, additional, Nagano, Hiroaki, additional, Okuno, Kiyotaka, additional, Itoh, Kyogo, additional, Zavadova, Eva, additional, Vocka, Michal, additional, Spacek, Jan, additional, Petruzelka, Lubos, additional, Konopasek, Bohuslav, additional, Dundr, Pavel, additional, Skalova, Helena, additional, Torigoe, Toshihiko, additional, Sato, Noriyuki, additional, Furuhata, Tomohisa, additional, Takemasa, Ichiro, additional, Van den Eynde, Marc, additional, Jouret-Mourin, Anne, additional, Machiels, Jean-Pascal, additional, Fredriksen, Tessa, additional, Lafontaine, Lucie, additional, Buttard, Bénédicte, additional, Church, Sarah, additional, Maby, Pauline, additional, Angell, Helen, additional, Angelova, Mihaela, additional, Vasaturo, Angela, additional, Bindea, Gabriela, additional, Berger, Anne, additional, Lagorce, Christine, additional, Patel, Prabhu S., additional, Vora, Hemangini H., additional, Shah, Birva, additional, Patel, Jayendrakumar B., additional, Rajvik, Kruti N., additional, Pandya, Shashank J., additional, Shukla, Shilin N., additional, Wang, Yili, additional, Zhang, Guanjun, additional, Masucci, Giuseppe V., additional, Andersson, Emilia K., additional, Grizzi, Fabio, additional, Laghi, Luigi, additional, Botti, Gerardo, additional, Tatangelo, Fabiana, additional, Delrio, Paolo, additional, Cilberto, Gennaro, additional, Marincola, Franco, additional, Sargent, Daniel J., additional, Fox, Bernard A., additional, Algazi, Alain, additional, Tsai, Katy, additional, Rosenblum, Michael, additional, Nandoskar, Prachi, additional, Li, Amy, additional, Nonomura, John, additional, Takamura, Kathryn, additional, Dwyer, Mary, additional, Browning, Erica, additional, Talia, Reneta, additional, Twitty, Chris, additional, Gargosky, Sharron, additional, Campbell, Jean, additional, Le, Mai, additional, Pierce, Robert H., additional, Daud, Adil, additional, Gartrell, Robyn, additional, Marks, Douglas, additional, Stack, Edward, additional, Lu, Yan, additional, Izaki, Daisuke, additional, Beck, Kristen, additional, Jia, Dan Tong, additional, Armenta, Paul, additional, White-Stern, Ashley, additional, Fu, Yichun, additional, Blake, Zoe, additional, Taback, Bret, additional, Horst, Basil, additional, Saenger, Yvonne M., additional, Leonardo, Steven, additional, Gorden, Keith, additional, Fulton, Ross B., additional, Fraser, Kathryn, additional, Kangas, Takashi O., additional, Walsh, Richard, additional, Ertelt, Kathleen, additional, Graff, Jeremy, additional, Uhlik, Mark, additional, Sims, Jennifer S., additional, Lei, Liang, additional, Tsujiuchi, Takashi, additional, Bruce, Jeffrey N., additional, Canoll, Peter, additional, Tolcher, Anthony W, additional, Alley, Evan W, additional, Chichili, Gurunadh, additional, Canoll, Jan E, additional, Moore, Paul, additional, Bonvini, Ezio, additional, Johnson, Syd, additional, Shankar, Sadhna, additional, Vasselli, James, additional, Wigginton, Jon, additional, and Powderly, John, additional
- Published
- 2016
- Full Text
- View/download PDF
35. USE IT OR LOSE IT: EAT AND EXERCISE DURING RADIOTHERAPY OR CHEMORADIOTHERAPY FOR PHARYNGEAL CANCERS
- Author
-
Hutcheson, Katherine A., Bhayani, Mihir K., Beadle, Beth M., Gold, Kathryn A., Shinn, Eileen H., Lai, Stephen Y., and Lewin, Jan
- Subjects
Adult ,Aged, 80 and over ,Male ,Antineoplastic Agents ,Pharyngeal Neoplasms ,Chemoradiotherapy ,Middle Aged ,Article ,Deglutition ,Exercise Therapy ,Eating ,Treatment Outcome ,Humans ,Female ,Aged ,Follow-Up Studies ,Retrospective Studies - Abstract
Data support proactive swallowing therapy during radiotherapy (RT) or chemoradiotherapy (CRT) for pharyngeal cancers. The benefits of adherence to a regimen of swallowing exercises and maintaining oral intake throughout treatment are reported, but independent effects are unclear.To evaluate the independent effects of maintaining oral intake throughout radiotherapy and adherence to preventive swallowing exercise.Retrospective observational study.The University of Texas MD Anderson Cancer Center, Houston.The study included 497 patients treated with definitive RT or CRT for pharyngeal cancer (458 oropharynx, 39 hypopharynx) between 2002 and 2008.Swallowing-related end points were final diet after RT or CRT and duration of gastrostomy dependence. Primary independent variables included oral intake status at the end of RT or CRT (no oral intake, partial oral intake, or full oral intake) and adherence to a swallowing exercise regimen. Multiple linear regression and ordered logistic regression models were analyzed.At the conclusion of RT or CRT, 131 patients (26%) had no oral intake and 74% maintained oral intake (167 partial [34%], 199 full [40%]). Fifty-eight percent (286 of 497) reported adherence to swallowing exercises. Maintenance of oral intake during RT or CRT and swallowing exercise adherence were independently associated with better long-term diet after RT or CRT (P = .045 and P.001, respectively) and shorter duration of gastrostomy dependence (P.001 and P = .007, respectively) in models adjusted for tumor and treatment burden.The data indicate independent, positive associations of maintenance of oral intake throughout RT or CRT and swallowing exercise adherence with long-term swallowing outcomes. Patients who either eat or exercise fare better than those who do neither. Patients who both eat and exercise have the highest rate of return to a regular diet and shortest duration of gastrostomy dependence.
- Published
- 2013
36. The microRNA-200/Zeb1 axis regulates ECM-dependent β1-integrin/FAK signaling, cancer cell invasion and metastasis through CRKL
- Author
-
Ungewiss, Christin, primary, Rizvi, Zain H., additional, Roybal, Jonathon D., additional, Peng, David H., additional, Gold, Kathryn A., additional, Shin, Dong-Hoon, additional, Creighton, Chad J., additional, and Gibbons, Don L., additional
- Published
- 2016
- Full Text
- View/download PDF
37. The Myb–p300 Interaction Is a Novel Molecular Pharmacologic Target
- Author
-
Liu, Xi, primary, Gold, Kathryn A., additional, and Dmitrovsky, Ethan, additional
- Published
- 2015
- Full Text
- View/download PDF
38. Abstract 3702: Integrated genomic and proteomic analysis identifies PTEN loss and AKT/MTOR as drivers of resistance to MEK inhibitors in NSCLC cells
- Author
-
Xia, Dianren, primary, Byers, Lauren Averett, additional, Diao, Lixia, additional, Wang, Jing, additional, Lin, Steven H., additional, Gibbons, Don Lynn, additional, Gold, Kathryn Ann, additional, Paul, Juliane, additional, Liu, Ningshu, additional, and Heymach, John V., additional
- Published
- 2014
- Full Text
- View/download PDF
39. A Phase I/II Study Combining Erlotinib and Dasatinib for Non-Small Cell Lung Cancer
- Author
-
Gold, Kathryn A., primary, Lee, J. Jack, additional, Harun, Nusrat, additional, Tang, Ximing, additional, Price, Justina, additional, Kawedia, Jitesh D., additional, Tran, Hai T., additional, Erasmus, Jeremy J., additional, Blumenschein, George R., additional, William, William N., additional, Wistuba, Ignacio I., additional, and Johnson, Faye M., additional
- Published
- 2014
- Full Text
- View/download PDF
40. Prediction of Survival in Resected Non–Small Cell Lung Cancer Using a Protein Expression–Based Risk Model: Implications for Personalized Chemoprevention and Therapy
- Author
-
Gold, Kathryn A., primary, Kim, Edward S., additional, Liu, Diane D., additional, Yuan, Ping, additional, Behrens, Carmen, additional, Solis, Luisa M., additional, Kadara, Humam, additional, Rice, David C., additional, Wistuba, Ignacio I., additional, Swisher, Stephen G., additional, Hofstetter, Wayne L., additional, Lee, J. Jack, additional, and Hong, Waun K., additional
- Published
- 2014
- Full Text
- View/download PDF
41. Abstract 1045: Proteomic analysis of effects of MEK inhibition with BAY86-9766 on LKB1/AMPK and mTOR pathway in lung cancer cell lines.
- Author
-
Gold, Kathryn A., primary, Byers, Lauren A., additional, Fan, You Hong, additional, Diao, Lixia, additional, Groth, Philip, additional, Paul, Julianne, additional, Wang, Jing, additional, Giri, Uma, additional, Gudikote, Jayanthi, additional, Tran, Hai T., additional, Coombes, Kevin R., additional, Minna, John D., additional, Liu, Ningshu, additional, and Heymach, John V., additional
- Published
- 2013
- Full Text
- View/download PDF
42. Characterizing the Molecular Spatial and Temporal Field of Injury in Early-Stage Smoker Non–Small Cell Lung Cancer Patients after Definitive Surgery by Expression Profiling
- Author
-
Kadara, Humam, primary, Shen, Li, additional, Fujimoto, Junya, additional, Saintigny, Pierre, additional, Chow, Chi-Wan, additional, Lang, Wenhua, additional, Chu, Zuoming, additional, Garcia, Melinda, additional, Kabbout, Mohamed, additional, Fan, You-Hong, additional, Behrens, Carmen, additional, Liu, Diane A., additional, Mao, Li, additional, Lee, J. Jack, additional, Gold, Kathryn A., additional, Wang, Jing, additional, Coombes, Kevin R., additional, Kim, Edward S., additional, Hong, Waun Ki, additional, and Wistuba, Ignacio I., additional
- Published
- 2013
- Full Text
- View/download PDF
43. New Strategies in Squamous Cell Carcinoma of the Lung: Identification of Tumor Drivers to Personalize Therapy
- Author
-
Gold, Kathryn A., primary, Wistuba, Ignacio I., additional, and Kim, Edward S., additional
- Published
- 2012
- Full Text
- View/download PDF
44. The BATTLE to Personalize Lung Cancer Prevention through Reverse Migration
- Author
-
Gold, Kathryn A., primary, Kim, Edward S., additional, Lee, J. Jack, additional, Wistuba, Ignacio I., additional, Farhangfar, Carol J., additional, and Hong, Waun Ki, additional
- Published
- 2011
- Full Text
- View/download PDF
45. Prevention of Bronchial Hyperplasia by EGFR Pathway Inhibitors in an Organotypic Culture Model
- Author
-
Lee, Jangsoon, primary, Ryu, Seung-Hee, additional, Kang, Shin Myung, additional, Chung, Wen-Cheng, additional, Gold, Kathryn Ann, additional, Kim, Edward S., additional, Hittelman, Walter N., additional, Ki Hong, Waun, additional, and Koo, Ja Seok, additional
- Published
- 2011
- Full Text
- View/download PDF
46. Abstract 3674: Gene expression analysis of field of cancerization in early stage NSCLC patients towards development of biomarkers for personalized prevention
- Author
-
Kadara, Humam, primary, Saintigny, Pierre, additional, Fan, Youhong, additional, Chow, Chi-Wan, additional, Chu, ZuoMing, additional, Lang, Wenhua, additional, Behrens, Carmen, additional, Gold, Kathryn, additional, Liu, Diane, additional, Lee, J. Jack, additional, Mao, Li, additional, Kim, Edward S., additional, Hong, Waun K., additional, and Wistuba, Ignacio I., additional
- Published
- 2011
- Full Text
- View/download PDF
47. TrxR, a New CovR-Repressed Response Regulator That Activates the Mga Virulence Regulon in Group A Streptococcus
- Author
-
Leday, Temekka V., primary, Gold, Kathryn M., additional, Kinkel, Traci L., additional, Roberts, Samantha A., additional, Scott, June R., additional, and McIver, Kevin S., additional
- Published
- 2008
- Full Text
- View/download PDF
48. Relationship Between Tumor Size and Survival in Non-Small-Cell Lung Cancer (NSCLC).
- Author
-
Jianjun Zhang, Gold, Kathryn A., Lin, Heather Y., Swisher, Stephen G., Yan Xing, Lee, J. Jack, Kim, Edward S., and William Jr., William N.
- Published
- 2015
- Full Text
- View/download PDF
49. 31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): late breaking abstracts
- Author
-
Althammer, Sonja, Steele, Keith, Rebelatto, Marlon, Tan, Tze Heng, Wiestler, Tobias, Schmidt, Guenter, Higgs, Brandon, Li, Xia, Shi, Li, Jin, Xiaoping, Antal, Joyce, Gupta, Ashok, Ranade, Koustubh, Binning, Gerd, Bellmunt, Joaquim, de Wit, Ronald, Vaughn, David J., Fradet, Yves, Lee, Jae Lyun, Fong, Lawrence, Vogelzang, Nicholas J., Climent, Miguel A., Petrylak, Daniel P., Choueiri, Toni K., Necchi, Andrea, Gerritsen, Winald, Gurney, Howard, Quinn, David I., Culine, Stéphane, Sternberg, Cora N., Mai, Yabing, Puhlmann, Markus, Perini, Rodolfo F., Bajorin, Dean F., Sharma, Padmanee, Callahan, Margaret K., Calvo, Emiliano, Kim, Joseph W., de Braud, Filipo, Ott, Patrick A., Bono, Petri, Pillai, Rathi N., Morse, Michael, Le, Dung T., Taylor, Matthew, Spilliopoulou, Pavlina, Bendell, Johanna, Jaeger, Dirk, Chan, Emily, Antonia, Scott J., Ascierto, Paolo A., Hennicken, Delphine, Tschaika, Marina, Azrilevich, Alex, Rosenberg, Jonathan, Levy, Ofer, Chan, Christopher, Cojocaru, Gady, Liang, Spencer, Ophir, Eran, Ganguly, Sudipto, Toporik, Amir, Kotturi, Maya, Kfir, Tal Fridman, Murter, Benjamin M., Logronio, Kathryn, Dassa, Liat, Leung, Ling, Greenwald, Shirley, Azulay, Meir, Kumar, Sandeep, Alteber, Zoya, Pan, Xiaoyu, Machlenkin, Arthur, Benita, Yair, Drake, Andrew W., Chajut, Ayelet, Salomon, Ran, Vankin, Ilan, Safyon, Einav, Hunter, John, Levine, Zurit, White, Mark, Leidner, Rom, Kang, Hyunseok, Haddad, Robert, Segal, Neil H., Wirth, Lori J., Ferris, Robert L., Hodi, F. Stephen, Sanborn, Rachel E., Gajewski, Thomas F., Sharfman, William, McDonald, Dan, Srivastava, Shivani, Gu, Xuemin, Phillips, Penny, Passey, Chaitali, Seiwert, Tanguy, Habtetsion, Tsadik, Zhou, Gang, Sakellariou-Thompson, Donastas, Haymaker, Cara, Creasy, Caitlin, Hurd, Mark, Uraoka, Naohiro, Canales, Jaime Rodriguez, Koptez, Scott, Hwu, Patrick, Maitra, Anirban, Bernatchez, Chantale, Coyle, Scott M., Roybel, Kole T., Rupp, Levi J., Santoro, Stephen P., Secrest, Stephanie, Spelman, Michael, Ho, Hanson, Gomes, Tina, Tse, Tiffany, Yung-Wu, Chia, Taunton, Jack, Lim, Wendell, Emtage, Peter, Moudgil, Tarsem, Ballesteros-Merino, Carmen, Hilton, Traci, Paustian, Christopher, Page, David, Urba, Walter, Fox, Bernard, Bell, Bryan, Patel, Ashish, Olafsen, Tove, Satpayev, Daulet, Torgov, Michael, Marchioni, Filippo, Romero, Jason, Jiang, Ziyue Karen, Zamilpa, Charles, Keppler, Jennifer S., Mascioni, Alessandro, Jia, Fang, Lee, Chen-Yu, Gudas, Jean, Sullivan, Ryan J., Hoshida, Yujin, Logan, Theodore, Khushalani, Nikhil, Giobbie-Hurder, Anita, Margolin, Kim, Roder, Joanna, Bhatt, Rupal, Koon, Henry, Olencki, Thomas, Hutson, Thomas, Curti, Brendan, Blackmon, Shauna, Mier, James W., Puzanov, Igor, Roder, Heinrich, Stewart, John, Amin, Asim, Ernstoff, Marc S., Clark, Joseph I., Atkins, Michael B., Kaufman, Howard L., Sosman, Jeffrey, Signoretti, Sabina, McDermott, David F., Anderson, Abraham A., Milhem, Mohammed M., Andtbacka, Robert H. I., Minor, David, Gorski, Kevin S., Baker, Daniel M., Hamid, Omid, Akporiaye, Emmanuel, Koguchi, Yoshinobu, Sutcliffe, Kim, Conder, Kristie, Marron, Thomas, Bhardwaj, Nina, Hammerich, Linda, George, Fiby, Kim-Schulze, Seunghee, Keler, Tibor, Davis, Tom, Crowley, Elizabeth, Salazar, Andres, Brody, Joshua, Monjazeb, Arta, Daly, Megan E., Riess, Jonathan, Li, Tianhong, Murphy, William J., Kelly, Karen, Hu, Zhiwei, Shen, Rulong, Campbell, Amanda, McMichael, Elizabeth, Yu, Lianbo, Ramaswam, Bhuvaneswari, London, Cheryl A., Xu, Tian, Carson, William, Kokolus, Kathleen M., Repasky, Elizabeth A., Schell, Todd D., Drabick, Joseph D., Messenheimer, David J., Jensen, Shawn, Rubinstein, Mark, Andrijauskaite, Kristina, Swiderska-syn, Marzena, Lind, Kristin, Choppin, Agnes, Roell, Marina K., Wrangle, John, Rhode, Peter, Wong, Hing, Ahmad, Shamim, Webb, Mason, Abu-Eid, Rasha, Shrimali, Rajeev, Verma, Vivek, Doroodchi, Atbin, Berrong, Zuzana, Yashar, David, Samara, Raed, Mkrtichyan, Mikayel, Khleif, Samir, Powell, Steven, Gitau, Mark, Sumey, Christopher, Terrell, Andrew, Lohr, Michele, Nowak, Ryan K., McGraw, Steven, Jensen, Ash, Blanchard, Miran, Gold, Kathryn A., Cohen, Ezra E. W., Ellison, Christie, Black, Lora, Lee, John, Spanos, William Chad, Wennerberg, Erik, Schwitzer, Emily, Lhuillier, Claire, Koelwyn, Graeme, Hiner, Rebecca, Jones, Lee, Demaria, Sandra, Amanda, Vandeveer, Greiner, John W., Schlom, Jeffrey, Bookstaver, Michelle, Jewell, Christopher M., Gunderson, Andrew, Boulmay, Brian, Li, Rui, Spieler, Bradley, Happel, Kyle, Feng, Zipei, Dubay, Christopher, Fisher, Brenda, Aung, Sandra, Mederos, Eileen, Bifulco, Carlo B., McNamara, Michael, Bahjat, Keith, Redmond, William, Ochoa, Augusto, Hu, Hong-Ming, Mehta, Adi, Lund-Johansen, Fridtjof, Bedu-Addo, Frank, Conn, Greg, King, Michael, Dutta, Panna, Shepard, Robert, Einstein, Mark, Adams, Sylvia, Wang, Ena, Jin, Ping, Novik, Yelena, Morrison, Debra, Oratz, Ruth, Marincola, Franco M., Stroncek, David, Goldberg, Judith, Formenti, Silvia C., Galon, Jérôme, Mlecnik, Bernhard, Marliot, Florence, Ou, Fang-Shu, Lugli, Alessandro, Zlobec, Inti, Rau, Tilman T., Nagtegaal, Iris D., Vink-Borger, Elisa, Hartmann, Arndt, Geppert, Carol, Roehrl, Michael H., Bavi, Prashant, Ohashi, Pamela S., Wang, Julia Y., Nguyen, Linh T., Han, SeongJun, MacGregor, Heather L., Hafezi-Bakhtiari, Sara, Wouters, Bradley G., Kawakami, Yutaka, Papivanova, Boryana, Xu, Mingli, Fujita, Tomonobu, Hazama, Shoichi, Suzuki, Nobuaki, Nagano, Hiroaki, Okuno, Kiyotaka, Itoh, Kyogo, Zavadova, Eva, Vocka, Michal, Spacek, Jan, Petruzelka, Lubos, Konopasek, Bohuslav, Dundr, Pavel, Skalova, Helena, Torigoe, Toshihiko, Sato, Noriyuki, Furuhata, Tomohisa, Takemasa, Ichiro, Van den Eynde, Marc, Jouret-Mourin, Anne, Machiels, Jean-Pascal, Fredriksen, Tessa, Lafontaine, Lucie, Buttard, Bénédicte, Church, Sarah, Maby, Pauline, Angell, Helen, Angelova, Mihaela, Vasaturo, Angela, Bindea, Gabriela, Berger, Anne, Lagorce, Christine, Patel, Prabhu S., Vora, Hemangini H., Shah, Birva, Patel, Jayendrakumar B., Rajvik, Kruti N., Pandya, Shashank J., Shukla, Shilin N., Wang, Yili, Zhang, Guanjun, Masucci, Giuseppe V., Andersson, Emilia K., Grizzi, Fabio, Laghi, Luigi, Botti, Gerardo, Tatangelo, Fabiana, Delrio, Paolo, Cilberto, Gennaro, Marincola, Franco, Sargent, Daniel J., Fox, Bernard A., Algazi, Alain, Tsai, Katy, Rosenblum, Michael, Nandoskar, Prachi, Li, Amy, Nonomura, John, Takamura, Kathryn, Dwyer, Mary, Browning, Erica, Talia, Reneta, Twitty, Chris, Gargosky, Sharron, Campbell, Jean, Le, Mai, Pierce, Robert H., Daud, Adil, Gartrell, Robyn, Marks, Douglas, Stack, Edward, Lu, Yan, Izaki, Daisuke, Beck, Kristen, Jia, Dan Tong, Armenta, Paul, White-Stern, Ashley, Fu, Yichun, Blake, Zoe, Taback, Bret, Horst, Basil, Saenger, Yvonne M., Leonardo, Steven, Gorden, Keith, Fulton, Ross B., Fraser, Kathryn, Kangas, Takashi O., Walsh, Richard, Ertelt, Kathleen, Graff, Jeremy, Uhlik, Mark, Sims, Jennifer S., Lei, Liang, Tsujiuchi, Takashi, Bruce, Jeffrey N., Canoll, Peter, Tolcher, Anthony W, Alley, Evan W, Chichili, Gurunadh, Canoll, Jan E, Moore, Paul, Bonvini, Ezio, Johnson, Syd, Shankar, Sadhna, Vasselli, James, Wigginton, Jon, and Powderly, John
- Subjects
Meeting Abstracts - Full Text
- View/download PDF
50. New strategies in immunotherapy for non-small cell lung cancer.
- Author
-
Carrizosa DR and Gold KA
- Abstract
Treatment for the most common form of cancer (lung cancer) has historically involved use of cytotoxic chemotherapy. With the advent of mutation analysis, more therapies beyond traditional cytotoxics have been discovered. Most recently, the use of immunotherapy has entered the treatment arsenal of non-small cell lung cancer (NSCLC). This review aims to summarize the current and future use of immunotherapy in the treatment of NSCLC.
- Published
- 2015
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.